Amicus Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J., Dec. 21, 2017 -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 36^th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 9, 2018 at 8:00am PT.

An audio webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.

CONTACTS:

Investors/Media:
Amicus Therapeutics
Sara Pellegrino, IRC
Senior Director, Investor Relations
[email protected]
(609) 662-5044

Media:
Pure Communications
Jennifer Paganelli
[email protected]
(347) 658-8290

FOLD–G